As of February 13, analysts’ consensus 12-month target price for Advance Auto Parts stock was $115.95.
For 4Q17, analysts expect Advance Auto Parts’ profit margins to remain weak on a quarter-over-quarter and year-over-year basis.
In 3Q17, Advance Auto Parts (AAP) reported revenues of $2.18 billion—a decrease of ~3.4% from its net revenues in 4Q16.
Capacity utilization is a key macroeconomic indicator that helps us understand the health of US industries.
Advance Auto Parts’ adjusted EPS could be $0.63 in 4Q17, which would be ~37% lower than its EPS of $1.00 in the same quarter in 2016.
The Federal Reserve’s report indicated that industrial production fell 0.1% in January as compared to a 0.9% increase in December.
As of February 13, 2018, Advance Auto Parts stock was trading at $106.22 with a positive return of ~6.6% in 1Q18.
Of the 12 analysts covering AMAG Pharmaceuticals, three have given the stock a “buy” or higher rating, and nine have given it a “hold.”
As of February 15, Home Depot was trading at $185.27. Analysts expect the company’s stock price to reach $210.45 in the next 12 months.
Analysts expect Home Depot (HD) to post an EPS (earnings per share) of $1.62 in 4Q17, which represents 12.5% growth from $1.44 in 4Q16.
Analysts expect Home Depot (HD) to post revenue of $23.67 billion, which represents 6.6% growth from $22.21 billion in 4Q16.
Home Depot (HD) is scheduled to announce its 4Q17 earnings before the market opens on February 20, 2018.
In 4Q17, Boston Scientific’s (BSX) Cardiovascular business segment reported sales of $913 million.
In 4Q17, Boston Scientific’s (BSX) Cardiovascular business registered strong YoY (year-over-year) sales growth of ~8.7% on a reported basis.
In 4Q17, Boston Scientific’s (BSX) MedSurg segment witnessed double-digit YoY (year-over-year) growth of ~14.2%, on a reported basis.
Boston Scientific’s 4Q17 revenue came in at $2.41 billion, exceeding Wall Street’s estimate of ~$2.38 billion.
BSX operates in three business segments: MedSurg, Rhythm Management, and Cardiovascular.
On February 1, 2018, Boston Scientific (BSX) announced its 4Q17 and 2017 earnings results.
On January 24, 2018, Boston Scientific (BSX) announced an investment deal, including an acquisition option, with Millipede.
Boston Scientific (BSX) has spent ~$89 million on the settlement of lawsuits related mainly to its mesh litigation.